Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Other Working Capital Changes: 2020-2024

Historic Other Working Capital Changes for Immuneering (IMRX) over the last 4 years, with Dec 2024 value amounting to -$1.5 million.

  • Immuneering's Other Working Capital Changes fell 1761.98% to -$1.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$300,102, marking a year-over-year increase of 20.76%. This contributed to the annual value of -$300,102 for FY2024, which is 20.76% up from last year.
  • As of Q4 2024, Immuneering's Other Working Capital Changes stood at -$1.5 million, which was down 330.22% from $644,549 recorded in Q3 2024.
  • Immuneering's 5-year Other Working Capital Changes high stood at $2.4 million for Q3 2022, and its period low was -$1.5 million during Q4 2024.
  • Its 3-year average for Other Working Capital Changes is -$26,552, with a median of -$127,288 in 2023.
  • As far as peak fluctuations go, Immuneering's Other Working Capital Changes spiked by 978.63% in 2021, and later plummeted by 2,051.85% in 2023.
  • Quarterly analysis of 5 years shows Immuneering's Other Working Capital Changes stood at -$70,051 in 2020, then crashed by 918.63% to -$713,561 in 2021, then soared by 100.57% to $4,083 in 2022, then plummeted by 2,051.85% to -$79,694 in 2023, then crashed by 1,761.98% to -$1.5 million in 2024.
  • Its Other Working Capital Changes stands at -$1.5 million for Q4 2024, versus $644,549 for Q3 2024 and $788,131 for Q2 2024.